Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:02 2026-05-08 am EDT			5-day change	1st Jan Change
112.85 ^EUR	-1.66%		+2.54%	-7.95%

May. 07	Genetix Selects Merck KGaA as Sole Testing Provider for Gene Therapies	MT
May. 07	Merck enters five-year agreement to provide end-to-end testing services for Genetix Biotherapeutics' commercial therapies	RE

Goldman Sachs trims Merck KGaA price target to 147 euros - "Buy"

Published on 04/16/2026 at 01:26 am EDT - Modified on 04/16/2026 at 06:16 am EDT

dpa-AFX - Translated by Marketscreener - See original

MERCK KGAA

-1.66%

NEW YORK (dpa-AFX Broker) - Goldman Sachs has lowered its price target for Merck KGaA from 153 to 147 euros, while maintaining a "Buy" rating. Analyst James Quigley anticipates a sluggish start to the year for the Darmstadt-based group, according to his preview of the quarterly report due in mid-May, published Wednesday evening. However, investor focus is expected to shift toward the strategy of the new CEO, who is set to take the helm on May 1./ag/gl

Original study publication: 15.04.2026 / 22:27 / BST First dissemination of original study: Date not specified in study / Time not specified in study / Time zone not specified in study

Latest news about Merck KGaA

May. 07	Genetix Selects Merck KGaA as Sole Testing Provider for Gene Therapies	MT
May. 07	Merck enters five-year agreement to provide end-to-end testing services for Genetix Biotherapeutics' commercial therapies	RE
May. 07	Merck and Genetix Biotherapeutics Enter Five-Year Agreement for Analytical and Biosafety Release Testing Services	CI
May. 07	MERCK KGAA : Buy rating from UBS	ZD
May. 05	Merck KGaA Opens New French Site to Boost Metrology, Inspection Tools Production	MT
May. 05	MERCK KGAA : JP Morgan reiterates its Buy rating	ZD
May. 04	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
May. 01	Merck bets on veteran leadership: Kai Beckmann takes the helm in Darmstadt	DP
Apr. 30	Merck KGaA Doses First Patient in Late-stage Trial for Lupus Drug	MT
Apr. 30	Merck Kgaa, Darmstadt, Germany Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations	CI
Apr. 30	MERCK KGAA : Deutsche Bank reiterates its Neutral rating	ZD
Apr. 29	Italian Pharma Group Chiesi to Acquire U.S. Rival KalVista	RE
Apr. 29	BofA Expects Merck KGaA's Q1 EBITDA to Beat Consensus; Buy Rating Kept	MT
Apr. 29	MERCK KGAA : Barclays sticks Neutral	ZD
Apr. 29	MERCK KGAA : JP Morgan keeps its Buy rating	ZD

Chart Merck KGaA

Duration

Period

MRK: Dynamic Chart

Company Profile

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (42.6%); - pharmaceutical products (40.8%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (16.6%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Switzerland (1.9%), Europe (23.7%), the United States (24.8%), North America (1.3%), China (13.7%), Asia/Pacific (19.2%), Latin America (6.9%), Middle East and Africa (3.7%).

Employees

59,077

Sector

Pharmaceuticals

Calendar

May. 13 - Earnings release - Q1 2026

More about the company